NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Says Results from an Independent Laboratory Confirm Avenova Kills SARS-Cov-2

There has been mounting pressure on the pharmaceutical industry to address the continuing pandemic with a possible vaccine, which can combat its spread. This has not been an easy task since every day there is the discovery of a new mode of transmission. However, there is still some light at the end of the tunnel; thanks to NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY).

According to laboratory results from an independent third-party, the biopharma says that a proprietary formulation of pure hypochlorous acid’; Avenova kills SARS-CoV-2. The first study to determine Avenova’s effectiveness was carried out on a hard surface with the USA-WA1/2020 strain of SARS-CoV-2.

The formulation was sprayed on the surface while observing a six to eight-inch distance until the surface became thoroughly wet. What followed was a 60 seconds verification of Avenova’s ability to incapacitate the virus completely.

Novabay Plans To Submit the Results to the EPA      

“Since Avenova’s inception, we have known it to be a powerful antimicrobial spray solution, effective against all types of pathogens,’’ NovaBay CEO, Justin Hall explained. He further noted that it could also be used on a wide variety of other viruses, bacteria, and fungi.

Given the encouraging results, NovaBay has confirmed its preparedness and eagerness to submit them to the EPA to list the EPA’s approved list of potential disinfectants for fighting SARS-CoV-2. The formulation of Avenova is on a pure hypochlorous acid approved by the FDA. The acid is non-toxic and safe for the delicate skin around the mouth, nose, and eyes.

However, this does not mean all hypochlorous acid products are safe, according to Hall. Some should not be in contact with the skin because they are not of a high pharmaceutical grade. Hence it is always recommended to seek a recommendation from a health professional.

Novabay’s Development of Other Non-Antibiotic Anti-Infective Products

It is a well-known fact that there is a huge shortage of novel therapies, which can effectively and simultaneously address the unmet therapeutic needs across the globe. This is the reason why NovaBay has maintained its zeal for the development of other non-antibiotic anti-infective products. It has two categories of products; the NEUTROX family and the AGANOCIDE compounds.